#SFHS2614107AAmendment to French Reimbursement Listing for PEGASYS Medicines
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order makes a narrow wording change to an earlier reimbursement listing for PEGASYS medicines. It removes the statement that patient cost-sharing is waived for the extended indication, while keeping the broader reimbursement extension wording in place. The practical effect is mainly administrative and reimbursement-related. Patients, prescribers, pharmacies, and health insurers should rely on the updated wording when checking coverage conditions for PEGASYS.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Updates the wording of the March 2026 reimbursement listing for PEGASYS medicines
- Removes the sentence stating that patient cost-sharing is waived for the extended indication
- Keeps the reimbursement extension for the relevant indication in the text
Obligations
What this law requires
Entities applying reimbursement conditions for PEGASYS specialties must use the revised wording stating only that coverage is extended to the specified indication, without treating the extended indication as exempt from patient cost-sharing under Article R. 160-8 of the Social Security Code.